Table 1. Adverse events considered related to panobinostat by treatment schedule and initial dose cohort.

Panobinostat-related toxicity	Arm A, n (%)			Arm B, n (%)
	G1 and 2	G3	G4	G1 and 2	G3	G4
Blood/bone marrow
Leukocytopenia	0	2 (10)	0	0	2 (10)	0
Neutropenia	0	1 (5)	1 (5)	0	4 (19)	0
Thrombocytopenia	0	5 (24)	1 (5)	0	3 (14)	1 (5)
Anemia	0	2 (10)	0	0	0	0
Cardiac	1 (5)	0	0	1 (5)	0	0
Constitutional symptoms
Fatigue	2 (10)	4 (19)	0	0	0	0
Weight loss	1 (5)	0	0	0	0	0
Gastrointestinal symptoms
Nausea/vomiting	4 (19)	1 (5)	0	3 (14)	0	0
Diarrhea	3 (14)	1 (5)	0	1 (5)	2 (10)	0
Colitis	0	1 (5)	0	0	0	0
Anorexia	1 (5)	0	0	0	0	0
Oral mucositis	0	0	0	1 (5)	0	0
Taste alteration	0	0	0	1 (5)	0	0
Pain	1 (5)	1 (5)	0	1 (5)	0	0
Headache	0	0	0	0	1 (5)	0
Renal failure	0	1 (5)	0	0	0	0
Rash	0	0	0	1 (5)	0	0
Sensory neuropathy	0	0	0	0	1 (5)	0
Metabolic/laboratory
Elevated liver function tests	0	0	0	2 (10)	2 (10)	0
Creatinine increased	1 (5)	0	0	0	0	0
Hyperuricemia	0	1 (5)	0	0	0	0